Name: Latest research reports of Gland Pharma Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Gland Pharma Ltd.
Rating: 5
Author: Motilal Oswal

Gland Pharma Ltd.

NSE: GLAND | BSE: 543245 | ISIN: INE068V01023 | Industry: Pharmaceuticals
| Mid-range Performer

1682.5000 -40.80 (-2.37%)

NSE Jan 23, 2026 15:31 PM

31.67% Gain from 52W Low

Volume: 85,262

Gland Pharma Ltd.

06 Aug 2025

1682.50

-2.37%

Strong margin gain boosts PAT by 50% YoY

Buy: Gland Pharma Ltd.

Target

Motilal Oswal

Gland Pharma (GLAND) posted revenue in line with our estimate in 1QFY26. However, EBITDA/PAT exceeded our estimates (13%/16% beat).

Gland Pharma Ltd. has an average target of 2250.00 from 3 brokers.